Recruiting • Phase NA • Stage III, IV • HER2 negative • Post-Menopausal • Non-interventional

The following is imported from ClinicalTrials.gov:

ACT-MBC: A Study of Circulating Tumor Cells (CTCs) in Metastatic Breast Cancer (MBC)

Brief Summary

ACT-MBC prospectively assesses the impact of CTCs on treatment decisions, response assessment and prognosis in MBC patients.

Description

Study Design

Eligibility Criteria

Arms and Intervention

• CellSearch Circulating Tumor Cells

Inclusion criteria

• invasive breast cancer with radiographic and/or clinical evidence of advanced metastatic or unresectable disease

• er+/her2- patients prior to starting 2nd line therapy or beyond or er/progesterone receptor (pr)/her2-negative (triple negative) patients prior to starting any line of therapy

• measurable and/or non-measurable disease is allowed

• male or female breast cancer is allowed

• age > 18 years

• willingness to provide mandatory blood specimens

• willing to return to enrolling institution for follow up imaging at least once

Exclusion criteria

• life expectancy of ≤ 6 months

• inability to provide blood samples based on the judgment of the treating provider